LUNG CANCER, NONSMALL CELL
Clinical trials for LUNG CANCER, NONSMALL CELL explained in plain language.
Never miss a new study
Get alerted when new LUNG CANCER, NONSMALL CELL trials appear
Sign up with your email to follow new studies for LUNG CANCER, NONSMALL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise against tough lung cancer
Disease control OngoingThis study tests whether combining three drugs—nivolumab, ipilimumab, and nintedanib—can shrink tumors in people with advanced non-small cell lung cancer that cannot be cured. About 66 adults with no other treatment options will take part. The goal is to find the safest dose and …
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Small study tracks risks of lung cancer combo therapy
Knowledge-focused OngoingThis study looks at side effects in people with stage IV non-small cell lung cancer who receive both immunotherapy (nivolumab or pembrolizumab) and palliative radiation to the chest. It involves 12 participants and aims to measure radiation-related toxicities and quality of life.…
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Scientists hunt for hidden cancer cells that survive targeted therapy
Knowledge-focused OngoingThis study looks at why lung cancer cells become resistant to a targeted drug called osimertinib. Researchers will collect blood and tissue samples from 80 patients to study these resistant cells. The goal is to find new ways to prevent the cancer from coming back.
Matched conditions: LUNG CANCER, NONSMALL CELL
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:28 UTC
-
Can blood tests predict lung cancer return after immunotherapy?
Knowledge-focused OngoingThis study follows 23 people with advanced non-small cell lung cancer who have finished at least 20 months of immunotherapy. Researchers want to see if certain immune markers and DNA in the blood can predict whether the cancer will come back. The goal is to better understand who …
Matched conditions: LUNG CANCER, NONSMALL CELL
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC